BMS Cuts Two Early Pipeline Bets as $13.1 Billion Quarter Carries the Story

Bristol Myers Squibb Discontinues Neuro Drug, Raises Full-Year Revenue Outlook

Bristol Myers Squibb has discontinued two early-stage pipeline candidates: BMS-986495 (PRX019), a neurodegeneration monoclonal antibody licensed from Prothena, and ORM-6151, a degrader-antibody conjugate for blood cancer acquired from Orum Therapeutics, following reviews of early clinical data. Despite these pipeline cuts, the company reported strong third-quarter financial results, with revenue increasing 7% to $13.1 billion, surpassing consensus estimates. This performance led BMS to raise its full-year revenue forecast to a new range of $49.75–$50.25 billion, signaling an improved commercial outlook.

• Discontinuation of Neurodegeneration Candidate: Bristol Myers Squibb decided not to advance BMS-986495 (PRX019), an investigational monoclonal antibody for neurodegeneration, after reviewing Phase 1 data. This asset was licensed from Prothena in May 2024 for an $80 million upfront payment and potential milestones up to $617 million. The decision reflects a strategic pipeline adjustment based on early clinical outcomes.
• Termination of Blood Cancer Program: The company also discontinued ORM-6151, an early-stage degrader-antibody conjugate for blood cancer, which was acquired from Orum Therapeutics in 2023 for $100 million upfront and up to $80 million in milestones. The decision was made after determining that the overall risk-benefit profile did not support further development, as stated in a September regulatory filing.
• Strong Financial Performance and Raised Guidance: BMS delivered robust third-quarter results, with revenue climbing 7% to $13.1 billion, exceeding the $12.75 billion consensus. This strong performance, driven by growth and legacy portfolios including subcutaneous Opdivo Qvantig and Eliquis, prompted the pharma to raise its full-year revenue guidance by 1% to $49.75–$50.25 billion, despite a $1.65 billion acquisition-related hit impacting EPS expectations.
• Ongoing Pipeline and Autoimmune CAR T Adjustments: While cutting some programs, BMS continues to advance others, including moponetug (PRX005) for Alzheimer’s disease in Phase 2, milvexian for secondary stroke prevention, Cobenfy for schizophrenia, and admilparant for pulmonary fibrosis. The company is also addressing safety concerns in its autoimmune CAR T program, zolacabtagene autoleucel (zola-cel), following a patient death and voluntary trial pauses, with adjustments made to restart clinical development.

Reviewing the Phase 1 Data for BMS-986495

The knowledge base does not have sufficient information to answer this question.

Navigating the Challenges in Neurodegeneration Drug Development

Alzheimer disease (AD) is the most common cause of dementia in the world with the prevalence expected to increase threefold to 152.8 million people by 2050. The current medications provide a short-term ameliorative effect, and this requires development of disease-modifying treatments, which address the biological pathogenesis.

• Symptomatic agents such as cholinesterase inhibitors and memantine remain useful for selected patients, but they do not directly modify the core neurodegenerative process.

• β-site APP-cleaving enzyme 1 (BACE1) and secretase inhibitors did not achieve success in clinical trials because of mechanism-based toxicity and cognitive impairment.

• New monoclonal antibodies such as lecanemab and donanemab have shown high amyloid plaque clearance and reduced cognitive deterioration, although the magnitude of clinical benefit is modest, treatment is restricted to carefully selected patients, and amyloid-related imaging abnormalities (ARIA) require structured monitoring.

• Tau-targeting approaches initially focused on post-translational modifications, inhibition of tau aggregation and stabilization of microtubules, however trials of many potential drugs were discontinued because of toxicity and/or lack of efficacy, and the majority of tau-targeting agents in clinical trials are now immunotherapies.

• Naringenin (NAR), a citrus-derived flavanone with antioxidant, anti-inflammatory and ability to modulate multiple cellular targets, showed neuroprotection in experimental models of AD, PD, HD, ALS, and MS, but clinical translation is challenged by poor bioavailability and novel delivery systems are being explored to enhance brain uptake.

BMS's Continued Pursuit of Novel Neurodegeneration Targets

Recent research frames neurodegeneration as driven by dysregulated neuroimmune connectivity, impaired proteostasis and mitochondrial clearance, rather than isolated proteinopathy. Plasma and imaging biomarkers including GFAP, sTREM2, YKL-40, neurofilament light chain, and TSPO PET are enabling in vivo tracking of these mechanisms alongside therapeutic exploration.

• Immuno-glial signaling and inflammasome pathways: Heterogeneous microglia and astrocyte subpopulations governed by TREM2–APOE, NF-κB, JAK/STAT, and NLRP3 inflammasome signaling sustain chronic inflammation, impair amyloid-β clearance, and accelerate tau pathology. Complement dysregulation via the C1q–C3 axis promotes aberrant synaptic pruning, while cytokine feedback loops involving IL-1β, TNF-α, and IFN-γ amplify neurotoxicity. Strategies described include selective NLRP3 inhibitors, TREM2 agonists, anti-cytokine biologics, and microbiome modulation via the gut–brain axis, with peripheral monocytes, macrophages, T and B lymphocytes, and neutrophils breaching the compromised blood–brain barrier.

• Neuron-microglia checkpoints and disease-associated microglia: CD200 and CX3CL1 expressed mainly on neurons and triggering receptor expressed on myeloid cells 2 (TREM2) expressed mainly on microglia mediate neuron-microglia interactions and contribute to Alzheimer's disease pathogenesis. Human cytomegalovirus immediate-early 2 (IE2) protein promoted microglia activation and upregulated expression of disease-associated microglia genes, with upregulation of immune and nervous system disease-related genes and increased amyloid precursor protein (APP) and p-Tau in IE2 transgenic mice.

• Autophagy-lysosome and mitophagy regulators: PINK1 accumulation recruits parkin, resulting in ubiquitination of mitochondrial proteins bound by p62/SQSTM1 and LC3 for degradation by mitophagy. Transcription factors Nrf2 and TFEB translocate to the nucleus following mitophagy induction, increasing p62/SQSTM1 expression, lysosomal proteins such as glucocerebrosidase and cathepsin D, and PGC-1α mRNA levels with increased mitochondrial content. Leucine-rich repeat kinase 2 (LRRK2) variants including G2019S and R1441C/G impair selective autophagy including mitophagy and chaperone-mediated autophagy, lysosomal function, synaptic vesicle endocytosis and glutamate release, with Rab12 recruited to damaged lysosomes leading to LRRK2-dependent increase in Rab10 phosphorylation.

• Misfolded protein immunotherapies: Mutant superoxide dismutase 1 (SOD1) and TAR DNA-binding protein 43kDa (TDP-43) provoke pathogenic pathways with cell-to-cell spreading behavior, supporting vaccination and antibody application. Intravenous full-length immunoglobulin targets extracellular proteins, while expression vectors for variable single chain fragments (scFv) with proteolytic signals target intracellular mislocalized or aggregated TDP-43, with vaccination efficacy shown against misfolded SOD1 in mutant SOD1 transgenic mice.

• Neurotrophic, metabolic and synaptic targets: Brain-derived neurotrophic factor (BDNF) promotes STAT3 phosphorylation and regulates neuronal autophagy, enhancing p-TrkB, P-STAT3, PINK1, and DJ-1, inhibiting p-α-syn (Ser129), with direct interaction between BDNF and STAT3 and between STAT3 and PI3K activating the PI3K/AKT/mTOR pathway. Succinate dehydrogenase complex iron sulfur subunit B (SDHB) was identified as a key risk factor where inhibition disrupts neuronal synaptic signaling, reduces PSD95 and SYP, and elevates Aβ and p-tau levels.

R&D Realignment: BMS Navigates Risk with Financial Resilience

The recent announcement from Bristol Myers Squibb, detailing the discontinuation of two early-stage pipeline candidates—BMS-986495 in neurodegeneration and ORM-6151 in blood cancer—serves as a stark reminder of the high-stakes nature of pharmaceutical R&D. These decisions, made after reviews of early clinical data, are a common yet critical aspect of portfolio management, reflecting a company's commitment to disciplined resource allocation. In an industry where the vast majority of experimental therapies fail to reach market, such early exits are often necessary to re-focus investment on programs with greater potential.

Crucially, these pipeline adjustments occur against a backdrop of robust financial health for BMS. The company reported strong third-quarter revenues, exceeding expectations, and subsequently raised its full-year revenue forecast. This financial resilience provides a significant strategic buffer, allowing the company to absorb R&D setbacks without immediate market apprehension. It signals that while innovation carries inherent risks, the strength of its commercialized portfolio can mitigate the impact of early-stage failures.

From a strategic perspective, the discontinuation of licensed/acquired assets suggests a rigorous internal evaluation process for external innovation. This could lead to a more selective approach for future partnerships, prioritizing opportunities that demonstrate a higher probability of success or a stronger strategic fit. However, this also highlights the inherent high attrition rate in early-stage R&D, particularly in challenging therapeutic areas. While current financial strength is reassuring, a long-term risk lies in the potential future revenue vulnerability if the existing commercial portfolio faces patent expirations or increased competition without a robust stream of new product approvals to fill the gap. The balance between aggressive innovation and sustainable commercial success remains a perpetual challenge, and these events underscore the continuous need for strategic foresight in pipeline development and financial planning.